(Q39271021)

10 September 2017

title

Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion (English)

1 reference

10 September 2017

0 references

7

0 references

Inge Marie Svane

8

0 references

Marco Donia

1

object named as

Marco Donia

1 reference

10 September 2017

6

Mads H Andersen

1 reference

10 September 2017

Sarah L Sendrup

3

1 reference

10 September 2017

Trine Zeeberg Iversen

4

1 reference

10 September 2017

Eva Ellebæk

5

1 reference

10 September 2017

language of work or name

English

0 references

publication date

27 September 2012

1 reference

Journal of Investigative Dermatology

10 September 2017

published in

1 reference

10 September 2017

volume

133

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

545-552

1 reference

Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Dissection of T-cell Antigen Specificity in Human Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Combination therapy: the next opportunity and challenge of medicine

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

The three Es of cancer immunoediting

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Eleventh international conference on progress in vaccination against cancer (PIVAC-11), 10-13 October 2011, Copenhagen, Denmark

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

The determination of an immunologically active dose of interferon-gamma in patients with melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Adoptive immunotherapy of cancer using CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Class II MHC molecules can use the endogenous pathway of antigen presentation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

IFN inducibility of major histocompatibility antigens in tumors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Suppression of T-cell responses by tumor metabolites

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

The known unknowns of antigen processing and presentation.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

The two faces of interferon-γ in cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.336

7 January 2021

Identifiers

DOI

10.1038/JID.2012.336

1 reference

Dimensions Publication ID

10 September 2017

1004223079

0 references

1 reference